Pharmacogenomics in Clinical Therapeutics

Amitava Dasgupta, Ph.D, DABCC, FACB, Professor of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, TX. Loralie J. Langman, Ph.D, DABCC, FACB, Associate Professor of Laboratory Medicine, Mayo Clinic, Rochester, MN.

List of Contributors, vii Preface, ix 1 Pharmacogenomics Principles: Introduction to Personalized Medicine, 1 Parvaz Madadi, PhD and Gideon Koren, MD 2 Traditional Therapeutic Drug Monitoring and Pharmacogenomics: Are They Complementary? 15 Christine L.H. Snozek, PhD, Loralie J. Langman, PhD, and Amitava Dasgupta, Ph.D 3 Pharmacogenomics Aspect of Warfarin Therapy, 26 Matthew D. Krasowski, MD, PhD 4 Pharmacogenetics and Cancer Chemotherapy, 39 Christine L.H. Snozek 5 Pharmacogenomic Considerations in Anesthesia and Pain Management, 53 Christine M. Formea, PharmD and Wayne T. Nicholson, MD, PharmD 6 Pharmacogenomics of Immunosuppressants, 70 Nicolas Picard, PharmD, PhD and Pierre Marquet, MD, PhD 7 Pharmacogenomics of Cardiovascular Drugs, 98 Linnea M. Baudhuin, PhD 8 Pharmacogenomic Aspects of Antiretroviral Therapy, 127 Natella Y. Rakhmanina, MD, PhD and John N. van den Anker, MD, PhD 9 Pharmacogenetics of Psychoactive Drugs, 144 Jorge L. Sepulveda, MD, PhD 10 Pharmacogenomic Aspects of Adverse Drug Drug Interactions, 176 Loralie J. Langman, PhD and Christine L.H. Snozek, PhD 11 Microarray Technology and Other Methods in Pharmacogenomics Testing, 185 Jorge L. Sepulveda, MD, PhD 12 Pharmacogenetic Testing in the Clinical Laboratory Environment, 201 Mark P. Borgman, PhD and Mark W. Linder, PhD Index, 225